Phase 2 Study of MK-2206, an Allosteric Inhibitor of AKT, as Second-Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer: A SWOG Cooperative Group Trial (S1005)

le Ramanathan, Ramesh K., McDonough, Shannon L., Kennecke, Hagen F., Iqbal, Syma, Baranda, Joaquina C., Seery, Tara E., Lim, Howard J., Hezel, Aram F., Vaccaro, Gina M., Blanke, Charles D.
Foilsithe in Cancer (2015)

Cetuximab combined with induction oxaliplatin and capecitabine, followed by neoadjuvant chemoradiation for locally advanced rectal cancer: SWOG 0713

le Leichman, Cynthia Gail, McDonough, Shannon L., Smalley, Stephen R., Billingsley, Kevin G., Lenz, Heinz-Josef, Beldner, Matthew A., Hezel, Aram F., Velasco, Mario R., Guthrie, Katherine A., Blanke, Charles D., Hochster, Howard S.
Foilsithe in Clin Colorectal Cancer (2017)

Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313

le Ramanathan, Ramesh K., McDonough, Shannon L., Philip, Philip A., Hingorani, Sunil R., Lacy, Jill, Kortmansky, Jeremy S., Thumar, Jaykumar, Chiorean, E. Gabriela, Shields, Anthony F., Behl, Deepti, Mehan, Paul T., Gaur, Rakesh, Seery, Tara, Guthrie, Katherine A., Hochster, Howard S.
Foilsithe in J Clin Oncol (2019)